Superworth

Baxter International price to free cash flow BAX

Market value divided by free cash flow over the last twelve months, since 2010.

Today, Oct 23, 2026
16.0×
10-year median
28.7×
Against its 10-year history
3rd
percentile: 0 is its lowest day, 100 its highest
10-year range
12.3× to 60.0×
Peer median
19.8×

Baxter International's price to free cash flow is 16.0× as of Oct 23, 2026.

That is below its ten-year median of 28.7×, lower than on 97% of days in the last ten years.

Over that time it ranged from 12.3× in May 2026 to 60.0× in May 2025.

The median for 10 medical instruments and supplies stocks of a similar size is 19.8×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far16.0×12.3×45.8×
202540.8×24.9×60.0×
202426.7×19.4×39.1×
202321.0×17.9×43.0×
202234.2×24.0×37.6×
202128.7×25.5×38.3×
202031.0×26.9×42.0×
201937.9×26.9×40.7×
201829.8×24.6×31.8×
201724.7×20.0×32.2×
201627.0×23.0×41.2×
201525.0×14.9×30.2×
201416.4×11.7×16.4×
201312.6×10.1×13.6×
20129.9×7.9×10.4×
20117.8×7.5×8.8×
20108.1×7.0×8.9×

Against its peers

Companies in Medical - Instruments & Supplies nearest Baxter International's size, closest first, today.

CompanyPrice to free cash flow
BAXBaxter International16.0×
PENPenumbra59.2×
SOLVSolventumn/m
COOCooper Companies17.2×
ALGNAlign Technology17.3×
GMEDGlobus Medical14.5×
PODDInsulet35.2×
MSAMSA Safety19.8×
WSTWest Pharmaceutical Services63.2×
MMSIMerit Medical Systems27.4×
HAEHaemonetics18.5×
Peer median19.8×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Baxter International

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.